Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Market Closed - Nasdaq Other stock markets 16:00:00 2024-12-04 EST			5-day change	1st Jan Change
40.58 ^USD	-1.62%		-9.72%	+76.97%

11-29	Protagonist Therapeutics Insider Sold Shares Worth $4,680,749, According to a Recent SEC Filing	MT
11-29	Protagonist Therapeutics Insider Sold Shares Worth $5,635,430, According to a Recent SEC Filing	MT

Presentation Operator MessageOperator (Operator)Good afterno...

This article is reserved for subscribers

To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Protagonist Therapeutics, Inc.

Protagonist Therapeutics Insider Sold Shares Worth $4,680,749, According to a Recent SEC Filing	11-29	MT
Protagonist Therapeutics Insider Sold Shares Worth $5,635,430, According to a Recent SEC Filing	11-29	MT
Protagonist Therapeutics Insider Sold Shares Worth $1,414,402, According to a Recent SEC Filing	11-29	MT
Protagonist Therapeutics, Inc. - Special Call	11-21
Protagonist Therapeutics, Inc. Announces Positive Topline Results from Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113)	11-18	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-07	CI
Earnings Flash (PTGX) PROTAGONIST THERAPEUTICS Posts Q3 Revenue $4.7M	11-07	MT
Wedbush Initiates Protagonist Therapeutics at Outperform With $58 Price Target	11-05	MT
TD Cowen Initiates Protagonist Therapeutics at Buy	09-24	MT
Protagonist Therapeutics, Inc. Announces Board Changes	09-20	CI
Truist Initiates Protagonist Therapeutics at Buy With $60 Price Target	09-09	MT
Protagonist Therapeutics Shares Fall After Q2 Revenue Miss	08-06	MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-06	CI
Protagonist Therapeutics, Inc. Announces Publication of Phase 1 Clinical Data on JNJ-2113 in the Journal	08-01	CI
Protagonist Therapeutics Appoints Newman Yeilding as Chief Scientific Advisor, Effective August 1, 2024	07-31	CI
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $48 From $39, Maintains Overweight Rating	07-25	MT
BTIG Raises Price Target on Protagonist Therapeutics to $51 From $41, Maintains Buy Rating	07-24	MT
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 1000	07-02	CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600 Health Care	07-02	CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P Composite 1500	07-02	CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600	07-02	CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell 3000 Value Index	06-30	CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell 2500 Value Index	06-30	CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell Small Cap Comp Value Index	06-30	CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell 2000 Value Index	06-30	CI